Intermittent androgen suppression in the treatment of metastatic prostate cancer

European Urology

Volumn 38, Issue 5, 2000, Pages 543-549

  Bouchot, Olivier ^a   Lenormand, Loïc ^a   Karam, Georges ^a   Prunet, Denis ^a   Gaschignard, Nicolas ^a   Malinovsky, J Marc ^a   Buzelin, J Marie ^a  

^a HÔTEL DIEU   (France)

Author keywords

Biochemical response; Intermittent endocrine therapy; Metastasis; Prostate cancer; Quality of life

Indexed keywords

ANDROGEN; ANTIANDROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG INTERMITTENT THERAPY; HORMONAL THERAPY; HORMONE RESPONSE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL TIME;

EID: 0033662035     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1159/000020353     Document Type: Article

References (17)

1. Studies on prostate cancer. I. Effect of castration, estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
2. Overview of phase lll trials on combined androgen treatment in patients with metastatic prostate cancer
3. Effects of androgen withdrawal on the stem cells composition of the Shinogi carcinoma
4. Pathological growth of androgen-sensitive tissues resulting from latent actions of steroid hormones
5. Hormonal control of growth and progression in tumors of Nb rats and a theory of action
6. Effects of intermittent androgen suppression on androgen-dependent tumors: Apoptosis and serum prostate specific antigen
7. A controlled trial of leuprolide with and without flutamide in prostate carcinoma
8. A quality of life instrument for use in international clinical trials in oncology
9. Quality of life in patients with prostatic cancer: Results from a Swedish population study
10. Effects of intermittent diethylstilbestrol diphosphate administration on the R3327 rat prostatic carcinoma
11. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP tumour model
12. Intermittent endocrine therapy for advanced treated prostate cancer
13. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
14. A pilot study of intermittent androgen deprivation in advanced prostate cancer
15. Intermittent therapy for prostate cancer: Endocrine-Related
16. Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy: Development of a prostate-specific module supplementing the EORTC QLQ-C30